Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trial

Takashi Kadowaki1,*, Hideaki Jinnouchi2, Kohei Kaku3, Malene L Herslov4, Jacob Hyllested-Winge5, Shuji Nakamura6

1Department of Metabolic Diseases, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, 2Iryo Houjin Shadan Jinnouchikai, Jinnouchi Hospital, Kumamoto, 3Department of Internal Medicine, Kawasaki Medical School, Okayama, 4Medical & Science, Novo Nordisk A/S, Søborg, Denmark, 5Medical & Scientific Affairs, Novo Nordisk Pharma Ltd, Tokyo, and 6Iryo Houjin Shadan Kowakai Heiwadai Hospital, Miyazaki, Japan

Keywords
Basal insulin, Clinical trial, Type 2 diabetes mellitus

*Correspondence
Takashi Kadowaki
Tel: +81-3-5800-8815
Fax: +81-3-5800-9797
E-mail address: kadowaki-3im@h.u-tokyo.ac.jp

J Diabetes Investig 2016; 7: 711–717
doi: 10.1111/jdi.12502

Clinical Trial Registry
ClinicalTrials.gov
NCT01880736 (NN1250-4060)

INTRODUCTION
Insulin is the most efficacious glucose-lowering therapy for the treatment of type 2 diabetes, and is typically initiated when patients are unable to achieve glycemic control with lifestyle changes and oral antidiabetic drugs (OADs)1,2. Because of the pharmacokinetic profiles of neutral protamine Hagedorn insulin and previously available basal insulin analogs, patients are required to take their basal insulin at the same time each day3. These strict dosing schedules might be difficult for patients to adhere to4, and can make patients reluctant to initiate and continue taking insulin5. Several studies have shown that patients frequently miss or mistime their insulin doses when injecting insulin would interfere with daily activities4,6,7. Furthermore, a lack of adherence to insulin has been shown to affect glycemic control8,9.

ABSTRACT
Aims/Introduction: This trial assessed the efficacy and safety of the possibility of varying the daily injection time of once-daily, long-acting basal insulin degludec (IDeg) in Japanese patients with type 2 diabetes inadequately controlled with insulin glargine.

Materials and Methods: This was a 26-week, multicenter, open-label, randomized, treat-to-target trial, with a 2 × 2 factorial design comparing IDeg flexible (allowing dosing ±8 h from an agreed dosing time) with IDeg fixed dosing (at the same time each day). It was carried out in 458 adult patients who were inadequately controlled on insulin glargine with or without oral antidiabetic drugs.

Results: The majority of doses were taken within 2 h of the agreed dosing time, showing a high level of adherence among Japanese patients. After 26 weeks, IDeg flexible was non-inferior to IDeg fixed with respect to change in glycated hemoglobin from baseline, estimated treatment difference 0.08% points (95% confidence interval −0.05; 0.22). Fasting plasma glucose decreased to a similar level with IDeg flexible and IDeg fixed, estimated treatment difference −0.18 mmol/L (95% confidence interval −0.48; 0.12). The rates of confirmed and nocturnal confirmed hypoglycemia were numerically, but not significantly, higher with IDeg flexible vs IDeg fixed dosing. The rates of adverse events with IDeg flexible and IDeg fixed dosing were similar.

Conclusions: These results showed the efficacy and safety of allowing patients to vary the time they dosed IDeg, when necessary, in Japanese patients with type 2 diabetes. Dosing of IDeg at a time convenient to the patient was non-inferior, with respect to glycated hemoglobin, to dosing at the same time each day.
Therefore, a basal insulin that affords flexibility in the time of
dosing, when necessary, without compromising efficacy or
safety, might make it easier for patients to adhere to their treat-
ment regimen. Insulin degludec (IDeg) is a new basal insulin
with a long duration of action, a half-life of more than 24 h and
a flat, stable profile, as assessed in Japanese10 and Caucasian
populations11,12. A large-scale IDeg phase 3a program (BEGIN)
showed that IDeg is non-inferior to insulin glargine (IGlar) in
treat-to-target trials, with respect to lowering of glycated hemoglo-
in (HbA1c), and is associated with a lower rate of nocturnal hypoglycemia13. One of the phase 3a trials was carried out
exclusively in Asian patients with type 2 diabetes, showing that
IDeg is efficacious and tolerable in this population, providing
similar improvements in long-term glycemic control to IGlar, at
a significantly lower rate of overall confirmed hypoglycemia
once stable glycemic control and insulin dosing were achieved14.

Two international, 26-week, phase 3a studies carried out as part
of the large-scale IDeg phase 3a program (BEGIN; one in
type 1 and one in type 2 diabetes) explored the use of a
flexible dosing regimen of IDeg (with alternating dosing
intervals of 8 and 40 h) over 26 weeks15,16. The use of these
extreme dosing intervals resulted in non-inferior HbA1c reduc-
tions and similar safety when compared with IGlar given at the
same time each day15,16. Furthermore, a 26-week extension of
the study in type 1 diabetes allowed patients to take their insu-
lin at any time of day, as long as there was a minimum of 8 h
and a maximum of 40 h between doses. Change in HbA1c with
this flexible dosing regimen was not statistically significantly
different to that with IGlar dosed at the same time each day15.
Furthermore, the mean fasting plasma glucose (FPG) at the
end of the extension was significantly lower with IDeg dosed
flexibly, and the rate of nocturnal confirmed hypoglycemia was
25% lower vs IGlar.

Before the present study, there were no data investigating the
efficacy and safety of IDeg when the time of dosing was
adjusted on a day-to-day basis in Japanese patients with type 2
diabetes. Furthermore, although the efficacy and safety of IDeg
have been investigated extensively in a large international clini-
cal trial program, the dose timing and methods of dose adjust-
ment used in the clinical trials might not be representative of
those used in clinical practice.

The aim of the present trial was to compare the efficacy and
safety of once-daily IDeg dosed in a regimen that allowed flexi-
ibility in dose timing with dosing at the same time each day,
with or without OADs, in Japanese patients with type 2 dia-
betes who were inadequately controlled with IGlar. This trial
was carried out in order to investigate a setting more closely
resembling that of clinical practice, and it also enabled investiga-
tion of the extent to which patients choose to utilize the flexi-
ble dosing option. The second aim of this trial was to compare
two titration algorithms (simple vs stepwise); these data are
presented in a separate manuscript (Kadowaki T, Jinnouchi H,
Kaku K, Hersløv ML, Hyllested-Winge J, Nakamura S, manu-
script in preparation).

**MATERIALS AND METHODS**

**Study design and participants**

This was a 26-week, multicenter, open-label, randomized, treat-
to-target phase 3b trial, carried out at 39 sites in Japan between
June 2013 and April 2014. The trial was registered at clinical-
trials.gov (NCT01880736), and was carried out in accordance
with the Declaration of Helsinki17 and ICH Good Clinical
Practice18.

Patients enrolled in the trial were aged ≥20 years, had a diag-
nosis of type 2 diabetes for ≥26 weeks before screening, HbA1c
7.0–9.5% (both inclusive), a body mass index ≤35 kg/m² and
were treated with IGlar ± OADs for at least 12 weeks; OAD
doses were stable during this period. Patients were allowed to
continue with up to three of the following OADs during the
study: metformin, sulfonylurea/glinide, dipeptidyl peptidase-4
inhibitor, alpha-glucosidase inhibitor or pioglitazone.

Patients were excluded if they had any disorder or disease
that the investigator considered might affect safety or protocol
compliance. Patients were also excluded if they met any of the
following criteria within 26 weeks of the screening visit: stroke,
decompensated heart failure, myocardial infarction, unstable
angina pectoris or coronary arterial bypass graft or angioplasty,
impaired renal function (serum creatinine ≥124 μmol/L for
men, ≥115 μmol/L for women), or had current or past malig-
nant neoplasms (except basal cell and squamous cell skin carci-
noma).

**Randomization and masking**

Randomization was carried out 1:1:1:1 using an interactive
voice/web-response system (Figure 1). All patients were treated
with once-daily IDeg, and were randomized to one of two dos-
ing schedules and one of two titration algorithms. The 2 × 2
factorial design was utilized to obtain data on two aspects of
IDeg dosing: flexible vs fixed time dosing, and simple vs step-
wise titration (Figure 1). In patients randomized to the IDeg
flexible arm, an ‘agreed dosing time’ was selected with the
investigator, and patients were allowed to dose IDeg ±8 h from
this agreed dosing time on occasions where dosing at the
agreed time was not possible or convenient. In the IDeg fixed
arm, IDeg could be dosed at any time of day, and an ‘agreed
dosing time’ was selected with the investigator at randomiza-
tion; the injection time was to be at approximately the same
time of day throughout the trial, as per the Japanese label19.

**Procedures**

IDeg 100 U/mL was taken subcutaneously using a FlexTouch
prefilled pen (Novo Nordisk, Bagsværd, Denmark). Patients
were switched from their prettrial IGlar dose to IDeg in a unit-
to-unit ratio at randomization.

Insulin dose was titrated once weekly to an FPG target of
4.0–5.0 mmol/L (71–90 mg/dL). Patients in the simple titration
arm based their titration on a single prebreakfast self-measured
blood glucose (SMBG) value, and increased their dose by two
units if above target and reduced it by two units if below target.
Patients in the stepwise arm titrated the dose based on the mean of three consecutive prebreakfast SMBG values; the dose was increased or decreased in multiples of two units to a maximum of eight units depending on the SMBG value (Kadowaki et al., manuscript in preparation).

**End-points**

The primary end-point of the trial was change from baseline in HbA1c after 26 weeks of treatment. Secondary efficacy end-points were the number of responders for HbA1c based on reaching the target of <7.0% after 26 weeks of treatment, change from baseline in FPG after 26 weeks of treatment, SMBG (8-point profile and mean of 8-point profile) and insulin dose after 26 weeks of treatment.

The incidence of treatment-emergent adverse events (AEs) was documented throughout the trial, and events were treated by established standards of care. The number of treatment-emergent episodes of confirmed hypoglycemia, defined as plasma glucose <3.1 mmol/L (56 mg/dL) or severe hypoglycemia, requiring third-party assistance, were documented. Nocturnal confirmed hypoglycemia was defined as confirmed hypoglycemia occurring between 00.01 and 05.59 h, both inclusive. After 26 weeks of treatment, change from baseline in bodyweight, vital signs, fundoscopy and electrocardiogram, and laboratory safety variables (hematology and biochemistry) were assessed. Laboratory analyses were carried out by Quintiles Central Laboratories (Tokyo, Japan).

**Statistical analysis**

The sample size was determined to meet the primary objective using a t-statistic under the assumption of a one-sided test of size 2.5% and a zero mean treatment difference, as well as a standard deviation of 1.3% for change in HbA1c. The total number of randomized participants was to be at least 452 participants in order to have at least 85% power in the evaluation of the per protocol analysis set.

The interaction between dosing regimen and titration algorithm based on a 2 x 2 factorial design was analyzed statistically for all end-points in order to investigate any possible interactions. As there were no statistically significant interactions for any end-points, it is considered valid to estimate one common treatment difference on dosing regimen (flexible vs fixed) regardless of titration algorithm (simple vs stepwise), and vice versa.

Change from baseline in HbA1c and FPG, and the mean of eight-point SMBG after 26 weeks of treatment, were analyzed using an analysis of variance with dosing scheme (IDeg flexible or IDeg fixed), titration scheme (IDeg simple or IDeg stepwise), interaction between dosing and titration scheme, antidiabetic therapy at screening and sex as fixed factors, and age and baseline HbA1c as covariates. Non-inferiority was confirmed if the upper limit of the two-sided 95% confidence interval for the treatment difference was 0.4% or less in change from baseline in HbA1c after 26 weeks of treatment. The proportion of treatment responders was analyzed using a logistic regression model. A mixed-effects model was fitted to analyze the eight-point SMBG profile data. The number of treatment-emergent confirmed hypoglycemic and nocturnal confirmed hypoglycemic episodes were analyzed separately using a negative binomial regression model with a log-link function and the logarithm of the time-period considered treatment-emergent as offset. For responders, SMBG and hypoglycemia, the fixed factors used in the analysis model, were the same as per the HbA1c analysis, with age as the covariate.

The full analysis set included all randomized patients, and was used to analyze HbA1c, FPG, SMBG and hypoglycemia. The safety end-points were summarized using the safety analysis set, which included all participants receiving at least one
dose of the investigational product. Missing values were imputed using last observation carried forward.

RESULTS
Of the 505 patients screened, 458 were randomized to receive trial product, 229 to the IDeg flexible and 229 to the IDeg fixed arm (Figure 2). In total, 96.9% of patients in the IDeg flexible arm and 98.7% in the IDeg fixed arm completed the trial. There were no major differences between the treatment groups in baseline and demographic characteristics or treatment at screening (Table 1, Table S1). Most (43.9%) patients were treated with two OADs, whereas 31.4% were treated with one OAD and 20.3% were treated with more than two OADs. Overall, the most common OAD used was metformin, followed by dipeptidyl peptidase-4 inhibitor and sulfonylurea. No statistically significant interactions for any end-points were found between dosing regimen and titration algorithm.

Insulin dose and dose timing
Patients in the IDeg flexible arm were allowed to dose ±8 h from their agreed dosing time on occasions where dosing at the same time was not possible or convenient. In total, 87.3% of IDeg flexible doses were taken within a time interval of 2 h or less from the agreed dosing time, compared with 97.0% of IDeg fixed doses (Table 2, Figure S1). In the IDeg flexible arm, 6.8% of doses were taken 2–4 h, and 5.4% of doses were administered 4–8 h from the agreed dosing time. This corresponded to 73 and 48% of patients in the IDeg flexible arm taking doses 2–4 and 4–8 h, respectively, from the agreed
dose of the investigational product. Missing values were imputed using last observation carried forward.

RESULTS
Of the 505 patients screened, 458 were randomized to receive trial product, 229 to the IDeg flexible and 229 to the IDeg fixed arm (Figure 2). In total, 96.9% of patients in the IDeg flexible arm and 98.7% in the IDeg fixed arm completed the trial. There were no major differences between the treatment groups in baseline and demographic characteristics or treatment at screening (Table 1, Table S1). Most (43.9%) patients were treated with two OADs, whereas 31.4% were treated with one OAD and 20.3% were treated with more than two OADs. Overall, the most common OAD used was metformin, followed by dipeptidyl peptidase-4 inhibitor and sulfonylurea. No statistically significant interactions for any end-points were found between dosing regimen and titration algorithm.

Insulin dose and dose timing
Patients in the IDeg flexible arm were allowed to dose ±8 h from their agreed dosing time on occasions where dosing at the same time was not possible or convenient. In total, 87.3% of IDeg flexible doses were taken within a time interval of 2 h or less from the agreed dosing time, compared with 97.0% of IDeg fixed doses (Table 2, Figure S1). In the IDeg flexible arm, 6.8% of doses were taken 2–4 h, and 5.4% of doses were

Table 1 | Baseline characteristics

| Characteristic | IDeg flexible | IDeg fixed |
|----------------|--------------|------------|
| Female, n (%)  | 84 (36.7)    | 82 (35.8)  |
| Race, Asian    | 100          | 100        |
| non-Indian (%) |              |            |
| Age (years)    | 60.1 ± 10.8  | 60.5 ± 10.5|
| Bodyweight (kg)| 67.0 ± 13.1  | 66.9 ± 12.3|
| BMI (kg/m²)    | 25.3 ± 3.7   | 25.2 ± 3.4 |
| Duration of diabetes (years) | 13.0 ± 7.5 | 13.7 ± 7.6 |
| HbA1c (%)      | 7.8 ± 0.6    | 7.8 ± 0.6  |
| FPG, mmol/L    | 7.4 ± 2.0    | 7.4 ± 2.0  |
| (mg/dL)        | (133.1 ± 36.6)| (132.9 ± 34.4) |
| Prestudy treatment, n (%) | 11 (4.8) | 9 (3.9) |
| Basal only     |              |            |
| Basal + 1 OAD  | 78 (34.1)    | 66 (28.8)  |
| Basal + 2 OADs | 95 (41.5)    | 106 (46.3) |
| Basal + ≥2 OADs| 45 (19.7)    | 48 (21.0)  |

Data are mean ± standard deviation unless otherwise stated. BMI, body mass index; FPG, fasting plasma glucose; IDeg, insulin degludec; n, number of patients; OAD, oral antidiabetic drug.

Figure 2 | Patient disposition. FAS, full analysis set; IDeg, insulin degludec; SAS, safety analysis set.
Table 2 | Insulin dose and dose timing

| Time difference between actual and agreed dosing time | IDeg flexible n = 229 | IDeg fixed n = 229 |
|-------------------------------------------------------|------------------------|-----------------------|
| Time (min)                                            | 24 ± 112               | 12 ± 55               |
| Absolute mean                                         | 58                     | 23                    |
| Median (min; max)                                     | 2 (–1000; 1385)        | 0 (–720; 850)         |

| Patients, Doses, n (%)                                | 40,543                  | 41,060                |
|-------------------------------------------------------|-------------------------|-----------------------|
| Total number of doses (n²)                            |                          |                       |
| ≤2 h                                                  | 227 (99.1)              | 229 (100)             |
| >2 and ≤4 h                                          | 167 (72.9)              | 109 (47.6)            |
| >4 and ≤8 h                                          | 109 (47.6)              | 72 (31.4)             |
| >8 h                                                  | 32 (14.0)               | 20 (8.7)              |
| Time not recorded                                     | 2 (0.9)                 | 1 (0.4)               |
| Dose (U/kg)                                           | 0.24 ± 0.14             | 0.23 ± 0.14           |
| Baseline                                              |                          |                       |
| Dose (U/kg)                                           | 0.40 ± 0.22             | 0.41 ± 0.21           |
| End-of-trial (week 25)                                |                          |                       |

Data are mean ± standard deviation. †Total number of doses excluding the first dose. IDeg, insulin degludec.

dosing time on one or more occasions. In comparison, 1.9 and 1.0% of doses in the IDeg fixed arm were taken 2–4 h and 4–8 h from the agreed dosing time, respectively (Table 2). The absolute mean time difference between actual and agreed dosing time appeared to be slightly higher with IDeg flexible compared with IDeg fixed dosing: 58 min vs 23 min (Table 2).

Basal insulin dose increased in both arms during the trial (Table 2). The mean daily insulin dose at the end of treatment was similar with IDeg flexible (0.40 U/kg, 28 U) and IDeg fixed dosing (0.41 U/kg, 28 U): the ratio of mean doses IDeg flexible/IDeg fixed (U/kg) was 1.00.

Glycemic control

During the 26 weeks of treatment, similar HbA1c reductions were observed in both arms. In the IDeg flexible arm, mean observed HbA1c decreased from 7.8 to 7.3%, with an observed mean (standard deviation) change from baseline of −0.54% points (0.76); and in the IDeg fixed arm, HbA1c decreased from 7.8 to 7.2%, with an observed mean (standard deviation) change from baseline of −0.62% points (0.75). Accordingly, the primary end-point of non-inferiority was met, with an estimated treatment difference of 0.08% points (95% confidence interval −0.05; 0.22; Figure 3). The proportion of patients in each arm who reached the target HbA1c <7.0% was 39.3% with IDeg flexible and 41.5% with IDeg fixed (not significant).

With IDeg flexible, the mean observed FPG decreased from 7.4 to 5.8 mmol/L, and with the IDeg fixed arm, it decreased from 7.4 to 6.0 mmol/L (Figure S2), resulting in a non-significant estimated treatment difference of −0.18 mmol/L (95% confidence interval −0.48; 0.12) after 26 weeks of treatment.

The mean eight-point SMBG profiles decreased in both treatment arms from baseline to end-of-trial (Figure S3), with no significant differences between treatments at any of the measured time-points or for the mean of the eight-point SMBG profile.

Hypoglycemia and adverse events

In total, the numbers, proportions and rates of AEs reported with IDeg flexible and IDeg fixed dosing were similar, with event rates of 355 (IDeg flexible) and 344 (IDeg fixed) per 100 patient-years of exposure (Table S2). Most AEs were mild in severity, and the most frequently reported AEs in both treatment arms were nasopharyngitis and diabetic retinopathy. None of the serious AEs in the IDeg flexible arm were considered possibly or probably related to investigational product. Two serious AEs with a possible or probable relationship to the investigational product occurred in the IDeg fixed arm: these were non-cardiac chest pain and hypoglycemia. One death (suicide) occurred in the IDeg flexible arm (with stepwise titration). This death was not considered related to the investigational product, and was the only AE leading to withdrawal during the trial. Five acute coronary syndrome events occurred during the trial in four patients; one of these events was adjudicated as a major adverse coronary event, an acute myocardial infarction in a patient in the IDeg fixed arm (with stepwise titration), which was judged as unlikely to be as a result of the investigational product. At end-of-trial, there were no clinically relevant differences in vital signs, physical findings or fundoscopy between the two dosing regimens.

One severe hypoglycemic episode occurred during the trial, in the IDeg fixed arm (simple titration scheme). There was no significant difference in the rate of confirmed hypoglycemia between arms, although the rate was numerically higher in the
IDeg flexible arm, with an estimated rate ratio IDeg flexible/IDeg fixed of 1.33 (95% confidence interval 0.95; 1.86; Figure S4a, Table S3). The rate of nocturnal confirmed hypoglycemia was also numerically, but not significantly, higher in the IDeg flexible vs IDeg fixed arm, estimated rate ratio 1.25 (95% confidence interval 0.71; 2.20; Figure S4b, Table S3).

**DISCUSSION**

The present trial showed that a flexible dosing regimen of IDeg (allowing dosing ±8 h from their agreed dosing time on occasions where dosing at the same time was not possible or convenient) in Japanese patients with type 2 diabetes was non-inferior, with respect to change in HbA1c, to IDeg dosed at the same time each day, with glycemic control improving in both arms vs prior treatment with IGLar. However, it should be noted that the majority of doses were taken within a 2-h window of the agreed dosing time (87% with IDeg flexible vs 97% with IDeg fixed). Although the data from the present trial show a high level of adherence to the agreed dosing time in Japanese patients with type 2 diabetes, it is important to recognize that they also show a need for some patients to be able to adjust dose timing in situations where dosing at the same time is not possible or convenient. Overall, 73 and 48% of patients in the IDeg flexible arm utilized the option of flexibility, and took their dose 2–4 and 4–8 h, respectively, from the agreed dosing time on one or more occasions. In general, the recommendation to dose IDeg at the same time every day remains; however, the present results show that there is a need for some flexibility in the dosing regimen by patients, and this can be accommodated with IDeg, without loss of efficacy or any other adverse clinical effects. The rates of confirmed and nocturnal confirmed hypoglycemic episodes were numerically higher with IDeg flexible compared with IDeg fixed dosing, although they were not statistically significantly different. Furthermore, a post-hoc analysis was carried out to investigate whether shorter or longer intervals between doses had an impact on the frequency of hypoglycemia. No specific patterns in the occurrence of hypoglycemic episodes by dosing interval were observed (data not shown).

Two international phase 3a trials have previously shown how IDeg dosed in a forced-flexible regimen (with intervals of 8–40 h) did not compromise efficacy or safety compared with IDeg dosed at the same time each day. Although the trial designs are different to the design reported here, these results all suggest that in clinical practice, some flexibility can be afforded by IDeg, which could help patients to better adhere to their treatment by reducing the treatment burden.

The results of the present randomized, controlled, 26-week, 2 x 2 factorial design trial show the efficacy and safety of allowing patients to vary the time they dosed the basal insulin degludec (±8 h from their agreed dosing time on occasions where dosing at the same time was not possible or convenient) in Japanese patients with type 2 diabetes inadequately controlled with IGLar with or without oral therapies. These data show a high level of adherence to the agreed dosing time in Japanese patients, with the majority of doses taken within a 2-h window of the agreed dosing time. IDeg used in a flexible dosing regimen effectively improved long-term glycemic control, as measured by HbA1c, and was non-inferior to a fixed-time dosing regimen. The rates of confirmed and nocturnal confirmed hypoglycemia were numerically, but not significantly, higher with flexible compared with fixed dosing.

**ACKNOWLEDGMENTS**

The authors thank the investigators, trial staff and patients for their participation. The authors also thank Adele Buss and Daria Renshaw of Watermeadow Medical, UK, for medical writing and editing assistance (supported by Novo Nordisk). The study was sponsored by Novo Nordisk A/S. The sponsor was responsible for the trial design, supply of trial products, monitoring, data collection, statistical analyses and preparation of the clinical study report.

**DISCLOSURE**

TK is a member of the National Advisory Board for Novo Nordisk Japan; reports funded research departments from MSD, Nippon Boehringer Ingelheim, Novartis and Novo Nordisk; lecture fees from Astellas, AstraZeneca, Eli Lilly, Kissei, Kowa, Mitsubishi Tanabe, MSD, Nippon Boehringer Ingelheim, Novo Nordisk, Ono, Sumitomo Dainippon and Takeda; manuscript fees from Eli Lilly; grants and endowments from Daiichi Sankyo, Mitsubishi Tanabe, Sumitomo Dainippon, and Takeda; funds for contracted research from Daiichi Sankyo, Sanwa Kagaku Kenkyusho Co., Ltd and Takeda; and funds for collaborative research from Daiichi Sankyo and Novartis. HJ has received lecture fees from AstraZeneca, Astellas Pharma, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Takeda, Novartis Pharmaceuticals, Novo Nordisk and Sanofi. KK is a member of advisory panels for Novo Nordisk, Sanwa Kagaku Kogyo, Takeda and Taisho Pharmaceutical Co., Ltd; has received scholarship grants from Chugai, Daiichi Sankyo, MSD, Novo Nordisk and Takeda; and has received speaker honoraria from MSD, Kowa, Sumitomo Dainippon Pharma, Novartis, Novo Nordisk, Takeda and Mitsubishi Tanabe Pharma. MLH and JH-W are employees of Novo Nordisk. SN has received honoraria for lectures from Novo Nordisk Pharma Ltd.

**REFERENCES**

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologica 2015; 58: 429–442.

2. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes
Association and the European Association for the Study of Diabetes. *Diabetes Care* 2009; 32: 193–203.

3. Evans M, Schumm-Draeger PM, Vora J, et al. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. *Diabetes Obes Metab* 2011; 13: 677–684.

4. Peyrot M, Barnett AH, Meneghini LF, et al. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. *Diabet Med* 2012; 29: 682–689.

5. Yoshioka N, Ishii H, Tajima N, et al. Differences in physician and patient perceptions about insulin therapy for management of type 2 diabetes: the DAWN Japan study. *Curr Med Res Opin* 2014; 30: 177–183.

6. Atsumi Y, Brod M, Barnett AH, et al. GAPP2: Global survey finds that a quarter of Japanese type 2 diabetes downplay insulin non-adherence to their healthcare professional. *Diabetologia* 2012; 55(Suppl. 1): S397.

7. Brod M, Rana A, Barnett AH. Adherence patterns in patients with type 2 diabetes on basal insulin analogues: missed, mistimed and reduced doses. *Curr Med Res Opin* 2012; 28: 1933–1946.

8. Donnelly LA, Morris AD, Evans JM. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. *QJM* 2007; 100: 345–350.

9. Randløv J, Poulsen JU. How much do forgotten insulin injections matter to haemoglobin A1C in people with diabetes? A simulation study. *J Diabetes Sci Technol* 2008; 2: 229–235.

10. Ikushima I, Kaku K, Hirao K, et al. Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients. *J Diabetes Invest* 2016; 7: 270–275.

11. Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. *Diabetes Obes Metab* 2012; 14: 859–864.

12. Heise T, Nosek L, Bottcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. *Diabetes Obes Metab* 2012; 14: 944–950.

13. Vora J, Christensen T, Rana A, et al. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. *Diabetes Ther* 2014; 5: 435–446.

14. Onishi Y, Iwamoto Y, Yoo SJ, et al. Insulin degludec compared with insulin glargine in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. *J Diabetes Investig* 2013; 4: 605–612.

15. Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): A 26-week randomized, treat-to-target trial with a 26-week extension. *J Clin Endocrinol Metab* 2013; 98: 1154–1162.

16. Meneghini L, Atkin SL, Gough SCL, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in people with type 2 diabetes. *Diabetes Care* 2013; 36: 858–864.

17. World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Last amended by the 59th WMA Assembly, Seoul, October 2008.

18. International Conference of Harmonisation. ICH Harmonised Tripartite Guideline. Good Clinical Practice 01 May 1996.

19. Novo Nordisk A/S. Last updated 2015. Tresiba (insulin degludec) label Japan. Available at: https://www.pmda.go.jp/index.html. Accessed 26 August 2015.

**SUPPORTING INFORMATION**

Additional Supporting Information may be found in the online version of this article:

**Figure S1** | Agreed dosing time schedule.
**Figure S2** | Fasting plasma glucose over time.
**Figure S3** | Mean eight-point self-measured blood glucose profiles at baseline and end-of-trial.
**Figure S4** | Cumulative confirmed (a) hypoglycemia and (b) nocturnal hypoglycemia.
**Table S1** | Oral antidiabetic drugs at screening.
**Table S2** | Adverse events.
**Table S3** | Summary of hypoglycemic episodes.